Intravenous thrombolytic therapy is the mainstay of treatment for acute ischemic stroke. Intravenous thrombolytic therapy reduce the functional disability and death, it is the main acute treatment method for ischemic stroke. It has to been done in 4.5 hours from symptom onset. Reducing the time every 15 minutes until the start of treatment, decreases mortality by 4%, increases the chance of survival from a stroke with minimal functional impairment by 4%. Information was obtained from medical records of patients who were admitted at Riga East Clinical University Hospital from January 2019 to January 2020 and received thrombolytic therapy. Medical records of 328 patients were analyzed. Of all patients, 54.3% (n=178) were women, 45.7% (n=150) - men. The average age of thrombolised patients was 73.37. Mean DNT was 43.8 minutes. NIHSS from 1 to 6 at admission were 40% (N=131) of patients, from 7 to 16 - 44% (N=143), upon 16 – 16% (N=53), no data 0% (N=1) On discharge these results were accordingly 62% (N=204), 15% (N=50), 4% (N=14), no data 9% (N=30), but exitus letalis - 9% (N30) of patients. In admission mRS one were 3% (N=11) of patients, two - 8% (N=25), three - 16% (N=54), four - 34% (N=110), five - 39% (N=127), no data 0% (N=1). On discharge results were accordingly zero til one mRS 22% (N=73), 16% (N=53), 15% (N=49), 17% (N=57), 11% (N=36), no data 9% (N=30) and exitus letalis - 9% (N=30) of patients. More than 2/3 of patients had DTN time of 45 minutes. NIHSS and mRS results improved after thrombolytic therapy.
- 3.4. Other publications in conference proceedings (including local)